Abstract | INTRODUCTION: METHODS: Consecutive patients from a prospective registry who underwent RFA of AF between April 2012 and March 2015 and were on apixaban or rivaroxaban were studied. Clinical variables and outcomes were noted. RESULTS: There were a total of 358 patients (n = 56 on apixaban and n = 302 on rivaroxaban). There were no differences in baseline characteristics between both groups. The last dose of rivaroxaban was administered the night before the procedure in 96% of patients. In patients on apixaban, 48% of patients whose procedure was in the afternoon took the medication on the morning of the procedure. TIA/CVA occurred in 2 patients (0.6%) in rivaroxaban group with none in apixaban group (p = 0.4). There was no difference in the rate of pericardial effusion between apixaban and rivaroxaban groups [1.7% vs 0.6% (p = 0.4)]. Five percent of patients in both groups had groin complications (p = 0.9). In apixaban group, all groin complications were small hematomas except one patient who had a pseudoaneurysm (1.6%). One pseudo- aneurysm, 1 fistula and 3 large hematomas were noted in patients on rivaroxaban (1.7%) with the rest being small hematomas. DOACs were restarted post procedure typically 4 h post hemostasis. CONCLUSIONS: Peri-procedural uninterrupted use of apixaban and rivaroxaban during AF RFA is safe and there are no major differences between both groups.
|
Authors | Jayasree Pillarisetti, Madhu Reddy, Mamatha Vodapally, Tulasi Annapureddy, Maruthsakhi Molugu, Donita Atkins, Sudharani Bommana, Rhea Pimentel, Raghuveer Dendi, Dhanunjaya Lakkireddy |
Journal | Indian pacing and electrophysiology journal
(Indian Pacing Electrophysiol J)
2020 Nov - Dec
Vol. 20
Issue 6
Pg. 261-264
ISSN: 0972-6292 [Print] Netherlands |
PMID | 32810538
(Publication Type: Journal Article)
|
Copyright | Copyright © 2020 Indian Heart Rhythm Society. Production and hosting by Elsevier B.V. All rights reserved. |